XCellAssay

XCellAssay

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

XCellAssay is a private, early-stage diagnostics company developing a novel bioassay platform for comprehensive chemical contaminant detection in drinking water. Founded in 2010 and based in Berkeley, California, the company leverages engineered cells and robotic detection to identify endocrine disruptors and other industrial chemicals beyond the EPA's standard 90-contaminant list. With recent non-dilutive grant funding and academic partnership support, XCellAssay is validating its technology with state water agencies and positioning itself to address a significant gap in environmental health monitoring.

Diagnostics

Technology Platform

Multiplexed bioassay platform using engineered cells (e.g., nuclear receptor assays) and robotic detection to identify chemical contaminants in water based on their biological activity.

Opportunities

A large market exists for testing the tens of thousands of industrial chemicals not monitored by the EPA.
Growing consumer demand for personalized environmental health data and increasing regulatory attention on emerging contaminants like PFAS and endocrine disruptors create strong tailwinds for a broad-spectrum, biologically relevant testing platform.

Risk Factors

Key risks include the technical challenge of validating a novel bioassay for diverse, real-world water matrices and achieving regulatory-grade reliability.
Commercial risks involve convincing consumers and budget-constrained public water systems to pay for non-mandated testing, and competing with established labs using traditional analytical chemistry.

Competitive Landscape

Competition includes large commercial water testing labs (e.g., Eurofins, SGS) using mass spectrometry, which is precise for targeted chemicals but expensive for broad panels. Other startups may be developing similar bioassay or sensor-based approaches. XCellAssay's differentiation is its focus on multiplexed, functional biological response data at a claimed low cost.